BR9800501B1 - derivado de isoxazol e crotonamida e uso do mesmo. - Google Patents
derivado de isoxazol e crotonamida e uso do mesmo.Info
- Publication number
- BR9800501B1 BR9800501B1 BRPI9800501-4A BR9800501A BR9800501B1 BR 9800501 B1 BR9800501 B1 BR 9800501B1 BR 9800501 A BR9800501 A BR 9800501A BR 9800501 B1 BR9800501 B1 BR 9800501B1
- Authority
- BR
- Brazil
- Prior art keywords
- isoxazole
- crotonamide
- derivatives
- crotonamide derivatives
- Prior art date
Links
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702988A DE19702988A1 (de) | 1997-01-28 | 1997-01-28 | Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9800501A BR9800501A (pt) | 1999-12-07 |
| BR9800501B1 true BR9800501B1 (pt) | 2010-05-18 |
Family
ID=7818547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9800501-4A BR9800501B1 (pt) | 1997-01-28 | 1998-01-28 | derivado de isoxazol e crotonamida e uso do mesmo. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US5977151A (pt) |
| EP (1) | EP0859000B1 (pt) |
| JP (1) | JP4163776B2 (pt) |
| KR (1) | KR100572808B1 (pt) |
| CN (1) | CN1120160C (pt) |
| AR (1) | AR010399A1 (pt) |
| AT (1) | ATE231495T1 (pt) |
| AU (1) | AU729750B2 (pt) |
| BR (1) | BR9800501B1 (pt) |
| CA (1) | CA2228060C (pt) |
| CZ (1) | CZ296122B6 (pt) |
| DE (2) | DE19702988A1 (pt) |
| DK (1) | DK0859000T3 (pt) |
| ES (1) | ES2189010T3 (pt) |
| HU (1) | HUP9800147A3 (pt) |
| PL (1) | PL194932B1 (pt) |
| PT (1) | PT859000E (pt) |
| RU (1) | RU2192421C2 (pt) |
| TR (1) | TR199800117A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
| WO2003042193A1 (en) * | 2001-11-09 | 2003-05-22 | Geneva Pharmaceuticals, Inc. | Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| US7157283B2 (en) * | 2002-08-02 | 2007-01-02 | 3M Innovative Properties Company | Continuous process for the production of combinatorial libraries of modified materials |
| US7632916B2 (en) * | 2002-08-02 | 2009-12-15 | 3M Innovative Properties Company | Process to modify polymeric materials and resulting compositions |
| US7125902B2 (en) * | 2004-05-28 | 2006-10-24 | Unitech Pharmaceuticals, Inc. | Methods, compounds, and diagnostics for cancer treatment |
| EP1879906A4 (en) * | 2005-01-05 | 2009-07-22 | Advanced Genetic Analysis Corp | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF |
| US8877791B2 (en) * | 2006-08-04 | 2014-11-04 | Beth Israel Deaconess Medical Center, Inc. | Inhibitors of pyruvate kinase and methods of treating disease |
| US20080085912A1 (en) * | 2006-10-06 | 2008-04-10 | Unitech Pharmaceuticals, Inc. | Isoxazole derivatives and methods of treating diseases |
| US20100213060A1 (en) | 2009-02-23 | 2010-08-26 | Bio-Rad Laboratories, Inc. | Aqueous transfer buffer |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法 |
| CA2760929C (en) | 2009-05-04 | 2018-01-02 | Agios Pharmaceuticals, Inc. | Pkm2 activators for use in the treatment of cancer |
| EP2448581B1 (en) | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| SG177434A1 (en) | 2009-06-29 | 2012-02-28 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| WO2012083246A1 (en) | 2010-12-17 | 2012-06-21 | Agios Pharmaceuticals, Inc. | Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| MX336022B (es) | 2010-12-21 | 2016-01-06 | Agios Pharmaceuticals Inc | Activadores de pkm2 bicíclicos. |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| PT2704721T (pt) | 2011-05-03 | 2018-06-14 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| SI3307271T1 (sl) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals, Inc. | Postopki za uporabo aktivatorjev piruvat kinaze |
| WO2020189676A1 (ja) * | 2019-03-19 | 2020-09-24 | 三井化学株式会社 | プロピレン系樹脂組成物、成形体およびプロピレン重合体 |
| CA3259546A1 (en) * | 2022-06-13 | 2023-12-21 | Yeefan Med Inc | METHODS FOR DETECTING B-ISOX PRECIPITIES OR CAPTURED PROTEINS AS BIOMARKERS OF BIOFLUID |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) * | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| GB8619432D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| DE3935016A1 (de) * | 1989-10-20 | 1991-04-25 | Behringwerke Ag | Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten |
| ES2102367T3 (es) * | 1990-05-18 | 1997-08-01 | Hoechst Ag | Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion. |
| US5744664A (en) * | 1990-07-05 | 1998-04-28 | Hoechst Aktiengesellschaft | Cycloolefin copolymers (COCS) as substrate material for liquid-crystal displays |
| EP0538783B1 (de) * | 1991-10-23 | 1995-09-27 | Hoechst Aktiengesellschaft | N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft |
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| DE4310964A1 (de) * | 1992-04-16 | 1993-10-21 | Merck Patent Gmbh | Aktivierte Trägermaterialien, ihre Herstellung und Verwendung |
| ES2124801T3 (es) * | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa. |
| WO1994024095A1 (en) * | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
| US6024957A (en) * | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
-
1997
- 1997-01-28 DE DE19702988A patent/DE19702988A1/de not_active Withdrawn
-
1998
- 1998-01-22 AT AT98101030T patent/ATE231495T1/de active
- 1998-01-22 EP EP98101030A patent/EP0859000B1/de not_active Expired - Lifetime
- 1998-01-22 PT PT98101030T patent/PT859000E/pt unknown
- 1998-01-22 DK DK98101030T patent/DK0859000T3/da active
- 1998-01-22 ES ES98101030T patent/ES2189010T3/es not_active Expired - Lifetime
- 1998-01-22 DE DE59806965T patent/DE59806965D1/de not_active Expired - Lifetime
- 1998-01-23 US US09/012,570 patent/US5977151A/en not_active Expired - Lifetime
- 1998-01-26 RU RU98102023/04A patent/RU2192421C2/ru not_active IP Right Cessation
- 1998-01-26 CA CA002228060A patent/CA2228060C/en not_active Expired - Fee Related
- 1998-01-26 AR ARP980100334A patent/AR010399A1/es active IP Right Grant
- 1998-01-26 TR TR1998/00117A patent/TR199800117A2/xx unknown
- 1998-01-26 CN CN98103677A patent/CN1120160C/zh not_active Expired - Fee Related
- 1998-01-26 KR KR1019980002288A patent/KR100572808B1/ko not_active Expired - Fee Related
- 1998-01-27 AU AU52748/98A patent/AU729750B2/en not_active Ceased
- 1998-01-27 CZ CZ0024998A patent/CZ296122B6/cs not_active IP Right Cessation
- 1998-01-27 JP JP01392298A patent/JP4163776B2/ja not_active Expired - Fee Related
- 1998-01-28 HU HU9800147A patent/HUP9800147A3/hu unknown
- 1998-01-28 BR BRPI9800501-4A patent/BR9800501B1/pt not_active IP Right Cessation
- 1998-01-28 PL PL324549A patent/PL194932B1/pl not_active IP Right Cessation
-
1999
- 1999-04-22 US US09/296,254 patent/US6121479A/en not_active Expired - Lifetime
-
2000
- 2000-05-30 US US09/580,625 patent/US6265588B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9800501B1 (pt) | derivado de isoxazol e crotonamida e uso do mesmo. | |
| FI970864A7 (fi) | Isoksatsolijohdannaiset | |
| FI955235A0 (fi) | Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö | |
| MX210114B (es) | Formulacion de cemento. | |
| DE69720896D1 (de) | Tonerkammer und Arbeitseinheit | |
| BR9609414B1 (pt) | Combinação de vacina e kit para produzir a mesma. | |
| FI940904L (fi) | Oksatsolidiinidionijohdannaiset, niiden valmistus ja käyttö | |
| DE69829686D1 (de) | Vorrichtung mit regulierbarem medium und dieses benutzende einrichtung | |
| DE69840474D1 (de) | Temperaturunempfindlicher siliziumoszillator und daraus erzeugte präzesionsspannungsreferenz | |
| NL1014545A1 (nl) | Oxim-derivaten en de toepassing daarvan als latente zuren. | |
| BR9708950A (pt) | Derivados de isoxazol e seu uso como herbicidas | |
| ID19828A (id) | Pakaian penyerap cairan tubuh sekali pakai dengan alat pengaman buangan | |
| BR9711191A (pt) | Composto e uso do mesmo | |
| BR9610109A (pt) | Fecho e uso mesmo | |
| BR9707812A (pt) | Composto composto farmacêutica e uso do composto | |
| DE69426326D1 (de) | Fungizide oxazolyl- und oxadiazolylderivate | |
| EE03563B1 (et) | Alküülaminobensotiasooli ja -bensoksasooli derivaadid | |
| ITBO950462A0 (it) | Pittura e relativo uso | |
| BR9703378A (pt) | Compostos de estilbeno e seu uso | |
| DE69632559D1 (de) | Aufladeelement, Arbeitseinheit und dieses Aufladeelement verwendendes elektrophotographisches Gerät | |
| DE69809465D1 (de) | Abfallverbrennungsvorrichtung | |
| BR7401412U (pt) | Estojo de uso pessoal | |
| NO985079D0 (no) | Eksplosiv formulering | |
| NL1007839A1 (nl) | Formulering en gebruik. | |
| BR9612248A (pt) | Corante de poliazo e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer |
Free format text: AVENTIS PHARMA DEUSTSCHLAND GMBH (DE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS. QUANTO A REIVINDICACAO 3, RESSALVA-SE O DISPOSTO DO ARTIGO 10 VIII DA LPI 9279/96. |
|
| B24H | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi) | ||
| B24F | Patent annual fee: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |